MMP2
Target has curated data in GtoImmuPdb
Target id: 1629
Nomenclature: MMP2
Family: M10: Matrix metallopeptidase
Annotation status:
Annotated and awaiting review. Please contact us if you can help with reviewing.
» Email us
This target is also described as a ligand entry: matrix metalloproteinase 2; matrix metalloproteinase 2; matrix metalloproteinase 2
Contents:
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 660 | 16q13-q21 | MMP2 | matrix metallopeptidase 2 | |
| Mouse | - | 662 | 8 C5 | Mmp2 | matrix metallopeptidase 2 | |
| Rat | - | 662 | 19p11 | Mmp2 | matrix metallopeptidase 2 | |
| Previous and Unofficial Names |
| TBE- 1 | gelatinase A | CLG4 | CLG4A | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) |
| Database Links |
|
| Specialist databases | |
| MEROPS | M10.003 (Hs) |
| Other databases | |
| BRENDA | 3.4.24.24 |
| CATH/Gene3D | 3.40.390.10, 2.10.10.10, 2.110.10.10, 1.10.101.10 |
| ChEMBL Target | CHEMBL333 (Hs), CHEMBL3095 (Mm), CHEMBL1075175 (Rn) |
| DrugBank Target | P08253 (Hs) |
| Ensembl Gene | ENSG00000087245 (Hs), ENSMUSG00000031740 (Mm), ENSRNOG00000016695 (Rn) |
| Entrez Gene | 4313 (Hs), 17390 (Mm), 81686 (Rn) |
| Human Protein Atlas | ENSG00000087245 (Hs) |
| KEGG Enzyme | 3.4.24.24 |
| KEGG Gene | hsa:4313 (Hs), mmu:17390 (Mm), rno:81686 (Rn) |
| OMIM | 120360 (Hs) |
| Orphanet | ORPHA123439 (Hs) |
| RefSeq Nucleotide | NM_001127891 (Hs), NM_004530 (Hs), NM_008610 (Mm), NM_031054 (Rn) |
| RefSeq Protein | NP_004521 (Hs), NP_001121363 (Hs), NP_032636 (Mm), NP_112316 (Rn) |
| UniProtKB | P08253 (Hs), P33434 (Mm), P33436 (Rn) |
| Wikipedia | MMP2 (Hs) |
| Enzyme Reaction |
||||
|
||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| MMP2 is included in GtoImmuPdb based on its potential involvement in asthma. |
| Immuno Process Associations | |||||||||
|
| Immuno Disease Associations | ||||||||||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||
|
||||||||||||
|
||||||||||||
References
1. Brown S, Bernardo MM, Li Z-H, Kotra LP, Tanaka Y, Fridman R, Mobashery S. (2000) Potent and Selective Mechanism-Based Inhibition of Gelatinases. J. Am. Chem. Soc., 122: 6799-6800.
2. Cataldo D, Munaut C, Noël A, Frankenne F, Bartsch P, Foidart JM, Louis R. (2000) MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol., 123 (3): 259-67. [PMID:11112863]
3. Fisher JF, Mobashery S. (2006) Recent advances in MMP inhibitor design. Cancer Metastasis Rev., 25 (1): 115-36. [PMID:16680577]
4. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett., 14 (1): 47-50. [PMID:14684295]
5. MRC. AZD6605 Matrix metallopeptidase 13 (MMP13) inhibitor. Accessed on 28/10/2014. Modified on 28/10/2014. MRC/AstraZeneca: Mechanisms of Disease Call, http://webarchive.nationalarchives.gov.uk/20120104105854/http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc008371.pdf
6. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]
7. Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P. (2013) Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 21 (21): 6456-65. [PMID:24071448]
8. Tuccinardi T, Martinelli A, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, Murphy G, Rossello A. (2006) Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem., 14 (12): 4260-76. [PMID:16483784]
How to cite this page
M10: Matrix metallopeptidase: MMP2. Last modified on 19/04/2017. Accessed on 19/08/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1629.
